Archive of press releases of TVM Capital Life Science portfolio companies.

› navigate
TVM Capital Life Science News

invendo medical closes € 20M equity capital funding led by Xeraya Capital

March 20th, 2014

Significant financing to accelerate industrialization and commercialization of invendo’s single-use colonoscope – Kissing, Germany – Garden City, NY — March 20, 2014 — invendo medical, manufacturer and distributor of a single-use and computer-assisted colonoscopy system, today announced the closing of a € 20.3 million ($ 28 million) financing round led […]

TVM Capital Life Science counts two successful biotech IPOs of portfolio in the U.S. market in the last two weeks – which brings the total to four IPOs within 10 months, raising $ 300 million

February 20th, 2014

Munich, Montreal,  February 19, 2014 — Biotech IPOs continue to roll on and it is an explicit pleasure for TVM Capital Life Science as an investor to be part of the now year-long biotech IPO boom on NASDAQ  which is one of the busiest IPO period in the history of […]


February 10th, 2014

February 6, 2014 – Argos Therapeutics, Inc. today announced the pricing of its initial public offering of 5,625,000 shares of common stock at a public offering price of $8.00 per share, before underwriting discounts.  All of the shares in the offering are being sold by Argos.  In addition, the underwriters […]

TVM Life Science Ventures VII Announces Investment in GLWL Research Inc.

January 13th, 2014

Montreal QC, January 13th, 2014 –TVM Life Science Ventures VII today announced the fund’s third investment – GLWL Research Inc., a company based in Montreal, Quebec. GLWL Research Inc. plans to develop, to proof-of-concept, GLWL-01, an investigational compound originally discovered by Eli Lilly and Company with the potential to treat […]

bluebird bio Appoints Dr James Mandell to its Board of Directors

January 9th, 2014

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 9, 2014– bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, announced today that James Mandell, M.D. has joined the company’s board of directors. In addition, bluebird bio announced that Axel Polack, M.D., general […]

TVM Capital Life Science enters into Collaboration with Hanwha Biologics

December 2nd, 2013

Montreal/Seoul, December 2, 2013 – TVM Capital Life Science and Hanwha Chemical Corporation Biologics Business Unit (“Hanwha Biologics”) announced today that both parties entered into a global collaboration agreement. TVM Capital Life Science is a successful international investment group operating since 1983 with offices in Montreal and Munich. Hanwha Biologics […]

Bukwang Pharm. Co. Ltd. enters into partnership with TVM Capital Life Science

December 2nd, 2013

Montreal, Munich/Seoul, 02.12.2013 –Bukwang Pharm. Co. Ltd. and TVM Capital Life Science announced today that both companies signed a global partnership agreement. Bukwang is a well-established pharmaceutical company engaged in the development, manufacture and distribution of pharmaceutical products with a company history of more than 50 years. The company’s products […]

TVM Capital to focus on Life Science Venture and Healthcare Private Equity Investing only

November 4th, 2013

Two independent investment teams to focus on Life Science Venture Capital investments in Western Europe and North America and on Healthcare Private Equity investments in the MENA region Vienna, 04.November 2013 – During BioEurope 2013 in Vienna, TVM Capital, who has long been a leading international investment firm, announced that […]

TVM Capital Life Science to collaborate with the Korea Drug Development Fund to support the pharmaceutical industry in Korea

October 4th, 2013

Munich/Montreal/Seoul, September 30, 2013 – TVM Capital Life Science announced today that the company entered into an MOU with the Korea Drug Development (“KDDF”) to support  Korea’s ability to develop new drugs that meet global standards. The MOU was signed and announced between the KDDF and TVM during ‘BIO KOREA […]

Evotec raises € 30 m from Biotechnology Value Fund

September 1st, 2013

Biotechnology Value Fund, L.P. and other affiliates of US Investment Firm BVF Partners L.P. (“BVF”) invest € 30 m in new Evotec shares In A Simultaneous transaction, BVF Aquires OPtion to buy Stake from VC Firm TVM Capital (“TVM”) Acceleration of capital-efficient Drug Discovery Strategy Hamburg, Germany – 31 August […]